Navigation Links
AxoGen, Inc. Receives Grant in Partnership with Vanderbilt University from U.S. Department of Defense
Date:5/23/2013

Alachua, FL (PRWEB) May 23, 2013

AxoGen, Inc. (OTCBB: AXGN), a leading regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, today announced that the Company and Vanderbilt University have been awarded a shared $1.1 million grant, for which AxoGen’s portion is approximately 35%, from the Congressional Directed Medical Research Programs administrated by the U.S. Department of Defense (DoD) to support the development and expansion of nerve repair technologies.

Erick DeVinney, Director Clinical and Translational Sciences at AxoGen, said, “We are excited that the Department of Defense has recognized and reinforced the clinical value of AxoGen’s peripheral nerve repair platforms in the treatment of traumatic injuries. This grant supports our goal of providing new, life improving solutions for peripheral nerve injuries for wounded warriors and for civilian patients.”

The grant was awarded by the DoD’s Peer Reviewed Orthopaedic Research Program (PRORP) to support a development program jointly led by Wesley Thayer, MD, PhD, Assistant Professor at Vanderbilt University’s Department of Plastic Surgery and Curt Deister, PhD, of AxoGen.

Dr. Thayer added, “Grant funding and collaboration with industry partners helps ensure the translation of innovative technologies from the research lab to clinical use in patients. We are pleased to partner with AxoGen to make advances in the field of peripheral nerve repair.”

AxoGen’s peripheral nerve regeneration technologies are also involved in additional PRORP grant-funded projects in collaboration with the regenerative medicine and orthopedic research divisions of two other prestigious academic institutions. For more information on AxoGen and its technology, please visit http://www.axogeninc.com.

About AxoGen, Inc.
AxoGen (AXGN) is a regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company’s innovative approach to regenerative medicine has resulted in first-in-class products that will define their product categories. AxoGen’s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa ECM coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. For more information, visit our website at http://www.axogeninc.com.

AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL.

Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “continue”, “may”, “should”, “will” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product commercialization and marketing efforts for its portfolio of peripheral nerve repair products, Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector, product development, and the intent to list on a national securities exchange. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10763755.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. AxoGen, Inc. Files Form S-1 Registration Statement
2. AxoGen, Inc. Announces CE Mark Approval for AxoGuard® Nerve Protector and AxoGuard® Nerve Connector
3. AxoGen, Inc. Announces Release Date of First Quarter 2013 Results and Conference Call
4. AxoGen, Inc. to Highlight Products at the American Academy of Orthopedic Surgeons 2013 Meeting
5. AxoGen, Inc. Appoints Shawn McCarrey as Vice President of Sales
6. AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at American Society for Peripheral Nerve & American Society for Reconstructive Microsurgery 2013 Meetings
7. AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at American Association for Hand Surgery 2013 Annual Meeting
8. AxoGen, Inc. to sponsor Educational Symposium and Panel Discussion at 2013 Annual Meetings of American Association for Hand Surgery, American Society for Peripheral Nerve, and American Society for Reconstructive Microsurgery
9. Fresh Healthy Vending Receives Recent National and Local Media Focus
10. Pamela Isom, President and CEO of ICE Safety Solutions Inc. Receives 2013 Women of Influence Recognition and Award
11. Heart valve repair innovator receives Cedars-Sinai Heart Institutes Corday Prize in Heart Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Remote Medical Technologies ... impressive transportable capabilities with their iMedHD2™ Portable Teleultrasound System. Compatible ... technology that delivers HD, dynamic, streaming ultrasound images and video to one or ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... provided a new $11,250,000 senior credit facility to Sunrise, Florida-based Management Health Systems, ... were used to facilitate a recapitalization of MedPro led by Harren Equity Partners. ...
(Date:1/19/2017)... ... January 19, 2017 , ... Workrite Ergonomics announced ... , The Tranquility privacy panel system was designed to deliver the ideal blend ... reduce noise and provide the visual privacy required to maintain concentration levels and ...
(Date:1/19/2017)... Ashland, VA (PRWEB) , ... January 19, 2017 , ... ... planning services to the eastern Virginia region, is inaugurating a charity event to honor ... community. , While on duty last year, Chad Phillip Dermyer and his fellow officers ...
(Date:1/19/2017)... Norwalk, CT (PRWEB) , ... January 19, 2017 ... ... board certified Reproductive Endocrinologists at Reproductive Medicine Associates of Connecticut (RMACT) have ... Hurwitz, Dr. Cynthia Murdock and Dr. Shaun Williams have each been chosen by ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor ... market is expected to grow at a CAGR of 27.1% ... 38.7% in the second half of the forecast period. The market ... to 2027. The market is estimated at $1,058 million in 2016, ... ...
(Date:1/19/2017)... 2017 James Gilbart ... Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement to European Oncology ... an article by James Gilbart and ...
(Date:1/19/2017)... , Jan. 19, 2017   Science Exchange , ... to announce that the first five replication studies ... have been published in eLife today. Despite intense ... the first practical evaluation of reproducibility rates that ... studies. Unlike other assessments of reproducibility, the results ...
Breaking Medicine Technology: